LifeMD, Inc. 8-K

What Happened
LifeMD, Inc. announced on June 22, 2026 (via Form 8‑K and an accompanying press release) a strategic co‑marketing collaboration with Antares Pharma, Inc. (a Halozyme subsidiary) to support a direct‑to‑patient self‑pay program for XYOSTED® (testosterone enanthate), the FDA‑approved once‑weekly subcutaneous testosterone auto‑injector. LifeMD entered into a Master Services Agreement and Statement of Work, and Specialty Pharmacy Services Agreements, under which LifeMD will serve as the exclusive telehealth co‑marketing partner and its pharmacy will be the preferred dispensing pharmacy, shipping XYOSTED directly to patients. The program is scheduled to launch in July 2026 and will initially be available in 37 states. The parties will form a joint steering committee and will jointly invest in consumer education and promotional initiatives; the filing discloses no financial terms.

Key Details

• Program launch: July 2026; initial availability in 37 states.
• Contracts: Master Services Agreement, Statement of Work, and Specialty Pharmacy Services Agreements executed with Antares Pharma, Inc.
• Roles: LifeMD named exclusive telehealth co‑marketing partner; LifeMD’s affiliated medical group will evaluate patients and LifeMD’s pharmacy is preferred dispenser shipping to patients’ homes.
• Term and governance: Initial term of three years with automatic one‑year renewals unless 90 days’ notice given; joint steering committee will oversee co‑funded marketing; either party may terminate the SOW if budgeted marketing investments are not met for two consecutive quarters.
• Disclosure: Press release attached as Exhibit 99.1; no financial commitments or dollar amounts were disclosed in the filing.

Why It Matters
The agreements formally position LifeMD as the exclusive telehealth partner and preferred pharmacy for the XYOSTED self‑pay program, potentially increasing patient referrals, telehealth utilization, and pharmacy dispensing volume tied to this product. The collaboration includes joint marketing investments and governance, indicating coordinated commercial efforts between LifeMD and Antares/Halozyme. Investors should note the filing contains no financial terms or revenue projections and the company makes no admission as to the materiality of the disclosure; monitor future filings and company updates for any disclosed financial impact or performance metrics.